INVESTIGADORES
SANCHEZ PEÑA Ricardo Salvador
artículos
Título:
Linear parameter-varying model to design control laws for an artificial pancreas
Autor/es:
PATRICIO COLMEGNA; RICARDO S. SÁNCHEZ PEÑA; RAVI GONDHALEKAR
Revista:
BIOMEDICAL SIGNAL PROCESSING AND CONTROL
Editorial:
ELSEVIER SCI LTD
Referencias:
Lugar: Amsterdam; Año: 2018 vol. 40 p. 204 - 213
ISSN:
1746-8094
Resumen:
tThe contribution of this work is the generation of a control-oriented model for insulin-glucose dynamicregulation in type 1 diabetes mellitus (T1DM). The novelty of this model is that it includes the time-varying nature, and the inter-patient variability of the glucose-control problem. In addition, the modelis well suited for well-known and standard controller synthesis procedures. The outcome is an averagelinear parameter-varying (LPV) model that captures the dynamics from the insulin delivery input tothe glucose concentration output constructed based on the UVA/Padova metabolic simulator. Finally, asystem-oriented reinterpretation of the classical ad-hoc 1800 rule is applied to adapt the model?s gain.The effectiveness of this approach is quantified both in open- and closed-loop. The first one by com-puting the root mean square error (RMSE) between the glucose deviation predicted by the proposedmodel and the UVA/Padova one. The second measure is determined by using the -gap as a metric todetermine distance, in terms of closed-loop performance, between both models. For comparison pur-poses, both open- (RMSE) and closed-loop (-gap metric) quality indicators are also computed for othercontrol-oriented models previously presented.This model allows the design of LPV controllers in a straightforward way, considering its affine depen-dence on the time-varying parameter, which can be computed in real-time. Illustrative simulations areincluded. In addition, the presented modeling strategy was employed in the design of an artificial pan-creas (AP) control law that successfully withstood rigorous testing using the UVA/Padova simulator, andthat was subsequently deployed in a clinical trial campaign where five adults remained in closed-loopfor 36 h. This was the first ever fully closed-loop clinical AP trial in Argentina, and the modeling strategypresented here is considered instrumental in resulting in a very successful clinical outcome.